Canberra: A COVID-19 vaccine candidate developed at Australia''s Flinders University has cleared the first phase of testing confirmed media reports on Friday. The Australian reported that the vaccine developed by Nikolai Petrovsky from Flinders University is the first Australian candidate to pass the first phase of the trials as it was found to be safe and generated an immune response in human subjects. Named "Covax-19," the vaccine was administered to 40 volunteers during the first phase of trials.
Phase two will begin in September, this would include up to 500 volunteers. "We have confirmed that the Covax-19 vaccine can induce ?appropriate antibody responses in human subjects," said Petrovsky, the founder of biotechnology company Vaxine was quoted as saying. None of the people who volunteered during the first phase developed significant side-effects or fever, and if Covax-19 manages to pass phase two, Vaxine would have to enroll up to 50,000 volunteers from around the world for phase three, said the report.
|